Santen: Verily, a U.S. company, establishes joint venture: Ophthalmic device development
February 4, 2020
Santen: U.S. Verily
Santen and Life Sciences Business / Verily Life Sciences LLC (Alphabet subsidiary) announced that they will establish a joint venture.
Support ophthalmic practice:
One in 30 people in the world has some eye health problems.
Approximately 80% of visual impairments can be prevented by early detection and treatment.
Digital tools contribute to more proactive solutions in the healthcare industry.
Direction of joint venture:
Santen’s expertise in ophthalmology and advanced technology,
Integrate Verily’s integrated medical device and machine learning development,
We aim to develop and commercialize original ophthalmic devices and comprehensive technical solutions.